Skip to content
Evigrade
CriticalProkinetic, peripheral dopamine D2 receptor antagonist×Class Ia antiarrhythmic (sodium channel blocker with intermediate kinetics)

Updated · Methodology

Mechanism

Domperidone is associated with QT prolongation. Epidemiological studies also link it to a higher risk of serious ventricular arrhythmias and sudden cardiac death, especially in people over 60, at doses above 30 mg a day and with QT-prolonging drugs (domperidone summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Quinidine, a class IA antiarrhythmic, prolongs the QT interval in a dose-related way, and this can lead to torsade de pointes, a life-threatening arrhythmia (quinidine label, US Food and Drug Administration, FDA). The Spanish domperidone SmPC explains that such combinations raise the risk of QT prolongation through pharmacodynamic or pharmacokinetic interactions. It lists quinidine among the contraindicated class IA antiarrhythmics (AEMPS). The liver metabolises both drugs mainly through CYP3A4. Quinidine also inhibits CYP2D6, but CYP2D6 is not among the enzymes that metabolise domperidone (domperidone SmPC, AEMPS, and FDA quinidine label). The documents give no data on how one drug changes the level of the other.

Symptoms

QT prolongation itself causes no symptoms and shows only on an electrocardiogram (ECG), while an arrhythmia causes palpitations, dizziness and fainting. Besides torsade de pointes, quinidine can cause frequent extrasystoles, ventricular tachycardia, ventricular flutter and ventricular fibrillation. The risk of torsade de pointes rises with a slow heart rate, low potassium, magnesium or calcium and high quinidine levels, but it can also occur without these factors (quinidine label, US Food and Drug Administration, FDA). With domperidone, QT prolongation and torsade de pointes have been reported very rarely, and these reports included people with other risk factors, electrolyte disturbances or concomitant medicines (domperidone summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS).

Management

The combination is contraindicated. The Spanish domperidone summary of product characteristics (SmPC) contraindicates domperidone with QT-prolonging drugs and names both quinidine and hydroquinidine (domperidone SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Domperidone is also contraindicated in known QT prolongation, significant electrolyte disturbances, bradycardia and heart disease such as congestive heart failure (AEMPS). Use quinidine with extreme care in people with a pre-existing long QT syndrome, a history of torsade de pointes of any cause, or previous marked lengthening of the heart-rate-corrected QT interval (QTc) in response to quinidine or other drugs that prolong ventricular repolarisation (quinidine label, US Food and Drug Administration, FDA). In people with heart disease, the label generally advises starting quinidine and changing its dose where continuous monitoring and resuscitation are available. If the QRS complex widens to 130% of baseline or QTc reaches 130% of baseline and exceeds 500 ms, reduce the dose or stop quinidine (FDA quinidine label). If domperidone and quinidine have nevertheless been taken together and signs of arrhythmia appear, stop domperidone (AEMPS). In haemodynamically unstable polymorphic ventricular tachycardia, including torsade de pointes, stop quinidine and perform immediate cardioversion or overdrive pacing. Look for low potassium, magnesium and calcium and, if possible, correct them promptly (FDA quinidine label, overdosage section).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Domperidone

Other interactions with Quinidine